How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,896 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Topical treatments for scalp psoriasis. Full Text available with Trip Pro

Topical treatments for scalp psoriasis. People with chronic plaque psoriasis often have lesions on the scalp. Hair makes the scalp difficult to treat and the adjacent facial skin is particularly sensitive to topical treatments.To assess the efficacy and safety of topical treatments for scalp psoriasis.We searched the following databases up to August 2015: the Cochrane Skin Group Specialised Register, CENTRAL (2015, Issue 7), MEDLINE (from 1946), EMBASE (from 1974) and LILACS (from 1982). We (...) also searched five trials registers, screened abstracts of six psoriasis-specific conferences and checked the reference lists of included studies for further references to relevant randomised controlled trials.Randomised controlled trials (RCTs) with a parallel-group, cross-over or within-patient design of topical treatments for people of all ages with scalp psoriasis.Two authors independently carried out study selection, data extraction and 'Risk of bias' assessment. Disagreements were settled

2016 Cochrane

142. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. (Abstract)

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Antibodies targeting interleukin (IL)-23 and IL-17A effectively treat moderate-to-severe psoriasis. ECLIPSE is the first comparator study of an IL-23p19 inhibitor, guselkumab, versus an IL-17A inhibitor, secukinumab. The primary objective of this study was to show superiority of clinical response at week 48 for guselkumab versus secukinumab.In (...) this phase 3, multicentre, double-blind, randomised, comparator-controlled trial at 142 outpatient clinical sites in nine countries (Australia, Canada, Czech Republic, France, Germany, Hungary, Poland, Spain, and the USA), eligible patients were aged 18 years or older, had moderate-to-severe plaque-type psoriasis, and were candidates for phototherapy or systemic therapy. Eligible patients were randomly assigned with permuted block randomisation using an interactive web response system to receive either

2019 Lancet Controlled trial quality: predicted high

143. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. (Abstract)

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Psoriasis is an autoimmune disease that affects approximately 100 million people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment. We aimed to compare the efficacy and safety of risankizumab with adalimumab in patients with moderate-to-severe plaque psoriasis.IMMvent was a phase 3, randomised (...) , double-blind, active-comparator-controlled trial completed at 66 clinics in 11 countries. Eligible patients were aged 18 years or older with moderate-to-severe chronic plaque psoriasis. Patients were randomly assigned 1:1 using interactive response technology to receive 150 mg risankizumab subcutaneously at weeks 0 and 4 or 80 mg adalimumab subcutaneously at randomisation, then 40 mg at weeks 1, 3, 5, and every other week thereafter during a 16-week double-blind treatment period (part A). For weeks

2019 Lancet Controlled trial quality: predicted high

144. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis Full Text available with Trip Pro

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review

2019 EvidenceUpdates

145. Oral fumaric acid esters for psoriasis. Full Text available with Trip Pro

Oral fumaric acid esters for psoriasis. Psoriasis is a chronic inflammatory skin condition that can markedly reduce life quality. Several systemic therapies exist for moderate to severe psoriasis, including oral fumaric acid esters (FAE). These contain dimethyl fumarate (DMF), the main active ingredient, and monoethyl fumarate. FAE are licensed for psoriasis in Germany but used off-licence in many countries.To assess the effects and safety of oral fumaric acid esters for psoriasis.We searched (...) trials (RCTs) of FAE, including DMF monotherapy, in individuals of any age and sex with a clinical diagnosis of psoriasis.Two review authors independently assessed trial quality and extracted data. Primary outcomes were improvement in Psoriasis Area and Severity Index (PASI) score and the proportion of participants discontinuing treatment due to adverse effects.We included 6 studies (2 full reports, 2 abstracts, 1 brief communication, and 1 letter), with a total of 544 participants. Risk of bias

2015 Cochrane

146. Anti-TNF agents for paediatric psoriasis. Full Text available with Trip Pro

Anti-TNF agents for paediatric psoriasis. Psoriasis is a chronic skin disease that may develop at any age. Estimates for the United States and Europe suggest that psoriasis accounts for 4% of skin diseases in children. In most cases, the condition is mild and can be treated with creams. However, a small percentage of children have moderate to severe disease that requires drugs, such as ciclosporin or methotrexate, and some will require injections with newer biological agents, such as anti-TNF (...) (tumour necrosis factor) drugs. Anti-TNF drugs (among them etanercept, infliximab, and adalimumab) are designed to reduce inflammation in the body caused by tumour necrosis factor. Evidence for the safety and efficacy of these biological agents in paediatric psoriasis is lacking.To assess the efficacy and safety of anti-TNF agents for the treatment of paediatric psoriasis.We searched the following databases up to July 2015: the Cochrane Skin Group Specialised Register, the Cochrane Central Register

2015 Cochrane

147. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis Full Text available with Trip Pro

Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.We assembled a retrospective cohort of commercially insured adults in the USA diagnosed with PsO or PsA between 2015 and 2018. Exposure was dispensation

2019 EvidenceUpdates

148. Infliximab (Inflectra) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis

Infliximab (Inflectra) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis Final Appraisal Recommendation Advice No: 4214 – December 2014 Infliximab (Inflectra ® ? ) 100 mg powder for concentrate for solution for infusion Submission by Hospira UK Ltd Additional note(s): ? Please refer to the Summary of Product Characteristics for the full licensed indication. ? Please refer to the NICE website for full guidance on NICE recommendations, including any (...) specific restrictions on the use of the technology. ? In accordance with EMA guidance, the licence for the use of infliximab (Inflectra ® ? ) in rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis was granted on the basis of assumed bioequivalence. ? Due to the potential for small differences between biosimilars from different manufacturers and/or the reference product infliximab (Remicade ® ), post-marketing pharmacovigilance is essential

2015 All Wales Medicines Strategy Group

149. Infliximab (Remsima) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis

Infliximab (Remsima) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, psoriatic arthritis and psoriasis Final Appraisal Recommendation Advice No: 4314 – December 2014 Infliximab (Remsima ® ? ) 100 mg powder for concentrate for solution for infusion Submission by Celltrion Healthcare Ltd/Napp Pharmaceuticals Ltd Additional note(s): ? Please refer to the Summary of Product Characteristics for the full licensed indication. ? Please refer to the NICE website for full guidance on NICE (...) recommendations, including any specific restrictions on the use of the technology. ? In accordance with EMA guidance, the licence for the use of infliximab (Remsima ® ? ) in rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis was granted on the basis of assumed bioequivalence. ? Due to the potential for small differences between biosimilars from different manufacturers and/or the reference product infliximab (Remicade ® ), post-marketing pharmacovigilance is essential

2015 All Wales Medicines Strategy Group

150. Adalimumab (Humira) and plaque psoriasis in children: no better than other immunosuppressants

Adalimumab (Humira) and plaque psoriasis in children: no better than other immunosuppressants Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants'', 1 July 2016 {1} {1} {1} | | > > > In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants FREE DOWNLOAD In a trial in 114 children, the efficacy of adalimumab was not notably different from that of methotrexate, and its adverse effects profile did not appear to be more favourable. Full text

2016 Prescrire

151. Taltz (ixekizumab) - To treat adults with moderate-to-severe plaque psoriasis

Taltz (ixekizumab) - To treat adults with moderate-to-severe plaque psoriasis TALTZ (ixekizumab) Injection U.S. Department of Health and Human Services Search FDA Submit search TALTZ (ixekizumab) Injection TALTZ (ixekizumab) Injection Company: Eli Lilly and Company Application No.: 125521 Approval Date: 03/22/2016 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2016 FDA - Drug Approval Package

152. Taltz (ixekizumab) - Psoriasis

Taltz (ixekizumab) - Psoriasis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 25 February 2016 EMA/CHMP/190631/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Taltz International non-proprietary name (...) NAPSI Nail Psoriasis Severity Index NMSC non-melanoma skin cancer NRI nonresponder imputation NRS Numeric Rating Scale PASI Psoriasis Area and Severity Index PPASI Psoriasis Palmoplantar Severity Index PSAB Psoriasis Skin Appearance Bothersomeness PSSI Psoriasis Scalp Severity Index Q2W every 2 weeks Q4W every 4 weeks Q12W every 12 weeks QIDS-SR16 Quick Inventory of Depressive Symptomatology–Self Report (16 Items) sPGA static Physician Global Assessment TE-ADA treatment-emergent anti-drug antibodies

2016 European Medicines Agency - EPARs

153. Flixabi (infliximab) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis

Flixabi (infliximab) - rheumatoid arthritis, Crohn?s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 1 April 2016 EMA/CHMP/272283/2016 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Flixabi International non (...) in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint CHMP assessment report EMA/CHMP/272283/2016 Page 4/86 damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1). Psoriasis Flixabi is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate

2016 European Medicines Agency - EPARs

154. Psoriasis: assessment and management

Psoriasis: assessment and management Psoriasis: assessment and management Psoriasis: assessment and management Clinical guideline Published: 24 October 2012 nice.org.uk/guidance/cg153 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psoriasis: assessment and management (CG153) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 57Contents Contents Overview 4 Who is it for? 4 Introduction 5 Patient

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

155. Cosentyx (secukinumab) - To treat adults with moderate-to-severe plaque psoriasis

Cosentyx (secukinumab) - To treat adults with moderate-to-severe plaque psoriasis Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - COSENTYX (secukinumab) Company: Novartis Pharmaceuticals Corporation Application No.: 125504 Approval Date: 1/21/2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package

156. Betamethasone for Adults with Scalp Psoriasis

Betamethasone for Adults with Scalp Psoriasis Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types (...) , posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Betamethasone for Adults with Scalp Psoriasis: A Review of the Clinical and Cost

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

157. MiR-21 binding site SNP within ITGAM associated with psoriasis susceptibility in women. Full Text available with Trip Pro

MiR-21 binding site SNP within ITGAM associated with psoriasis susceptibility in women. Great progress has been made in the understanding of inflammatory processes in psoriasis. However, clarifying the role of genetic variability in processes regulating inflammation, including post-transcriptional regulation by microRNA (miRNA), remains a challenge.We therefore investigated single nucleotide polymorphisms (SNPs) with a predicted change in the miRNA/mRNA interaction of genes involved (...) in the psoriasis inflammatory processes.Studied SNPs rs2910164 C/G-miR-146a, rs4597342 T/C-ITGAM, rs1368439 G/T-IL12B, rs1468488 C/T-IL17RA were selected using a bioinformatics analysis of psoriasis inflammation-associated genes. These SNPs were then genotyped using a large cohort of women with psoriasis (n = 241) and healthy controls (n = 516).No significant association with psoriasis was observed for rs2910164, rs1368439, and rs1468488 genotypes. However, the major allele T of rs4597342 -ITGAM was associated

2019 PLoS ONE

158. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. (Abstract)

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine signaling, are implicated in the pathophysiology of psoriasis. Selective inhibitors of TYK2 may be effective in treating psoriasis.We conducted a phase 2, double-blind trial of a TYK2 inhibitor, BMS-986165, in adults with moderate-to-severe psoriasis, excluding patients with a previous lack of response to agents targeting cytokine signaling through the same (...) tyrosine kinase pathway. Patients were randomly assigned to receive the drug orally at a dose of 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily or to receive placebo. The primary end point was a 75% or greater reduction from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12 (higher scores indicate greater severity of psoriasis).A total of 267 patients received at least one dose in an intervention group of the trial. At week 12

2018 NEJM Controlled trial quality: predicted high

159. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease Full Text available with Trip Pro

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease To evaluate the safety of adalimumab in pediatric patients who participated in clinical trials of juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and pediatric enthesitis-related arthritis), psoriasis, and Crohn's disease.This analysis included data from 7 global, randomized, and open-label AbbVie-sponsored clinical (...) . Across indications, the most commonly reported adverse events (events/100 patient-years) were upper respiratory tract infections (24.3), nasopharyngitis (17.3), and headache (19.9). Serious infections (4.0 events/100 patient-years) were the most frequent serious adverse events across indications; the most commonly reported was pneumonia (0.6 events/100 patient-years). Serious infection rates were 2.7, 0.8, and 6.6 events/100 patient-years in patients with juvenile idiopathic arthritis, psoriasis

2018 EvidenceUpdates

160. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. (Abstract)

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19 subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. We aimed to assess the efficacy and safety of risankizumab compared with placebo or ustekinumab in patients with moderate (...) -to-severe chronic plaque psoriasis.UltIMMa-1 and UltIMMa-2 were replicate phase 3, randomised, double-blind, placebo-controlled and active comparator-controlled trials done at 139 sites in Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Japan, Mexico, Poland, Portugal, South Korea, Spain, and the USA. Eligible patients were 18 years or older, with moderate-to-severe chronic plaque psoriasis. In each study, patients were stratified by weight and previous exposure to tumour necrosis

2018 Lancet Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>